Keybank National Association OH Acquires 3,052 Shares of Illumina, Inc. (NASDAQ:ILMN)

Keybank National Association OH lifted its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 0.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 395,066 shares of the life sciences company's stock after purchasing an additional 3,052 shares during the period. Keybank National Association OH owned about 0.25% of Illumina worth $31,345,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently modified their holdings of the business. IFP Advisors Inc grew its holdings in shares of Illumina by 19.1% during the fourth quarter. IFP Advisors Inc now owns 617 shares of the life sciences company's stock valued at $82,000 after buying an additional 99 shares during the last quarter. Oppenheimer Asset Management Inc. bought a new stake in shares of Illumina during the fourth quarter valued at about $901,000. Metis Global Partners LLC boosted its holdings in Illumina by 6.4% in the 4th quarter. Metis Global Partners LLC now owns 3,803 shares of the life sciences company's stock valued at $508,000 after purchasing an additional 228 shares during the period. Jones Financial Companies Lllp increased its position in shares of Illumina by 28.6% in the fourth quarter. Jones Financial Companies Lllp now owns 4,632 shares of the life sciences company's stock worth $619,000 after purchasing an additional 1,030 shares during the last quarter. Finally, SBI Securities Co. Ltd. purchased a new stake in Illumina during the fourth quarter valued at about $152,000. Institutional investors own 89.42% of the company's stock.

Illumina Price Performance

ILMN stock traded up $0.10 on Thursday, hitting $100.44. 1,423,748 shares of the company's stock traded hands, compared to its average volume of 2,139,499. The company has a current ratio of 1.86, a quick ratio of 1.48 and a debt-to-equity ratio of 0.63. The stock has a market cap of $15.90 billion, a price-to-earnings ratio of -16.55, a P/E/G ratio of 1.93 and a beta of 1.36. The stock has a fifty day moving average of $84.12 and a 200-day moving average of $98.32. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The life sciences company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.96 by $0.01. Illumina had a positive return on equity of 25.54% and a negative net margin of 22.25%. The business had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.03 billion. During the same quarter in the previous year, the business posted $0.98 EPS. The firm's quarterly revenue was down 1.4% compared to the same quarter last year. On average, analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ILMN has been the topic of a number of research analyst reports. Piper Sandler reduced their price target on Illumina from $190.00 to $185.00 and set an "overweight" rating on the stock in a report on Thursday, May 15th. Canaccord Genuity Group upped their target price on shares of Illumina from $87.00 to $99.00 and gave the company a "hold" rating in a report on Wednesday, June 11th. Robert W. Baird decreased their price target on Illumina from $127.00 to $90.00 and set a "neutral" rating on the stock in a report on Wednesday, March 5th. Royal Bank Of Canada lowered their target price on Illumina from $128.00 to $112.00 and set an "outperform" rating for the company in a research report on Tuesday, April 8th. Finally, Morgan Stanley decreased their price objective on Illumina from $136.00 to $100.00 and set an "equal weight" rating on the stock in a research report on Monday, May 12th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $127.39.

Insiders Place Their Bets

In related news, CFO Ankur Dhingra acquired 6,100 shares of the firm's stock in a transaction on Monday, May 12th. The shares were purchased at an average cost of $81.21 per share, for a total transaction of $495,381.00. Following the completion of the acquisition, the chief financial officer directly owned 24,906 shares in the company, valued at approximately $2,022,616.26. This trade represents a 32.44% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. 2.60% of the stock is currently owned by corporate insiders.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.